<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1266">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05144672</url>
  </required_header>
  <id_info>
    <org_study_id>AATHSH</org_study_id>
    <nct_id>NCT05144672</nct_id>
  </id_info>
  <brief_title>Irisin And Diabetic Nephropathy</brief_title>
  <official_title>Irisin Level in Patients With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes mellitus (DM) is a complex, multifactorial, chronic metabolic and endocrine&#xD;
      disorder. It has become a threat to global health. It has two types. It is estimated that the&#xD;
      number of people with type II will reach 700 million by 2045.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is associated with acute and chronic complications, acute complications include&#xD;
      hypoglycemia, diabetic ketoacidosis, hyperglycemic hyperosmolar state, and hyperglycemic&#xD;
      diabetic coma. Chronic complications are further divided into microvascular and macrovascular&#xD;
      complications. Chronic microvascular complications are neuropathy, retinopathy, and&#xD;
      nephropathy. The later one firstly diagnosed by microalbuminuria. whereas chronic&#xD;
      macrovascular complications are coronary artery disease (CAD), peripheral artery disease&#xD;
      (PAD), and cerebrovascular disease.&#xD;
&#xD;
      The conventional medications in diabetes treatment, oral and insulin, are focusing on insulin&#xD;
      secretion and insulin sensitisation. Oral antidiabetics include, Biguanides, Sulfonylureas,&#xD;
      Thiazolidinediones, DPP4 inhibitors, GLP-1 analogue, and SGLT2 inhibitors.&#xD;
&#xD;
      Irisin, a myokin and adipokine secreted by muscles and subcutaneous fat, is an interesting&#xD;
      peptide performing significant functions in human health. Irisin has been linked to human&#xD;
      obesity and insulin resistance status.&#xD;
&#xD;
      Irisin is involved in regulating the mitochondrial function of muscle cells, so increases&#xD;
      energy consumption of the body, promotes metabolism and reduces body weight so improves&#xD;
      insulin sensetivity. In our study we aim to clarify the effect of antidiabetics on serum&#xD;
      irisin in patients with typeII DM who developed diabetic nephropathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The relation between different stages of diabetic nephropathy and irisin level.</measure>
    <time_frame>1 year</time_frame>
    <description>measurement of irisin level in patients with diabetic nephropathy</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Irisin</condition>
  <arm_group>
    <arm_group_label>Patient Group</arm_group_label>
    <description>The patient group will include 60 patients with type II DM. They will be subdivided into three groups according to albumin-creatinine ratio ,normoalbuminuric group(less than 30mg/g),which will include 20 patients, microalbuminuric group (ACR =30-300 mg/), which will include 20 patients, and macroalbuminuric group (ACR more than 300mg/g),which will include 20 patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>control group will include 30 apparently healthy age-matched and sex-matched individuals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Laboratory tests</intervention_name>
    <description>Fasting blood glucose (FBG), postprandial blood glucose, total cholesterol (CHO), triglycerides (TG), high-density lipoprotein cholesterol and low-density lipoprotein cholesterol (LDL-C), urea, creatinine, and uric acid by point colorimetric assay.&#xD;
Serum irisin.</description>
    <arm_group_label>Patient Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anthropometric measurements</intervention_name>
    <description>Height, weight, waist circumference, and hip circumference were taken as a way of assessing the nutritional status and BMI</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrocardiogram and Fundus examination</intervention_name>
    <description>Fundus examination by direct ophthalmoscope</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Estimated glomerular filtration rate (eGFR)</intervention_name>
    <description>Estimated glomerular filtration rate (eGFR) was calculated by EPI equation.</description>
    <arm_group_label>Patient Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brachial index</intervention_name>
    <description>The ankle-brachial index test compares the blood pressure measured at your ankle with the blood pressure measured at your arm</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Laboratory tests</intervention_name>
    <description>Glycosylated haemoglobin. ACR,urinary albumin (mg) and creatinine (g).</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Abdominal ultrasound.</intervention_name>
    <description>It will be performed for patients only.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patients above 40 years with type 2 diabetes of at least two years duration complicated&#xD;
        with diabetic nephropathy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Any patients above 40 years with type 2 diabetes of at least two years duration complicated&#xD;
        with diabetic nephropathy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients below 40 yrs.&#xD;
&#xD;
          -  Patients with type 1 diabetes complicated with diabetic nephropathy&#xD;
&#xD;
          -  Type2 diabetes without nephropathy.&#xD;
&#xD;
          -  Diabetic nephropathy cases on dialysis due to other causes&#xD;
&#xD;
          -  Blood pressure more than 160/100&#xD;
&#xD;
          -  Acute coronary syndrome in the past 6 months&#xD;
&#xD;
          -  Non alcoholic fatty liver disease, impaired liver function.&#xD;
&#xD;
          -  Malignancy.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Acute infection, acute inflammation.&#xD;
&#xD;
          -  Severe renal impairment, and urinary tract infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hala Khalah Allah Khalifa El-shereef, MD</last_name>
    <phone>01120110000</phone>
    <email>dr_hala_elshereef@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marwa Kamal Abdo Khair Allah, MD</last_name>
    <phone>01097878113</phone>
    <email>Marwa.kamal82@hotmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Xuan X, Lin J, Zhang Y, Zhou L, Xu L, Jia J, Zhao B, Lin Z, Zhu Q, Li L, Wu T, Zhang S, Jiang H, Wang Y. Serum Irisin Levels and Clinical Implication in Elderly Patients With Type 2 Diabetes Mellitus. J Clin Med Res. 2020 Sep;12(9):612-617. doi: 10.14740/jocmr4261. Epub 2020 Aug 15.</citation>
    <PMID>32849950</PMID>
  </reference>
  <reference>
    <citation>Ravaut M, Sadeghi H, Leung KK, Volkovs M, Kornas K, Harish V, Watson T, Lewis GF, Weisman A, Poutanen T, Rosella L. Predicting adverse outcomes due to diabetes complications with machine learning using administrative health data. NPJ Digit Med. 2021 Feb 12;4(1):24. doi: 10.1038/s41746-021-00394-8.</citation>
    <PMID>33580109</PMID>
  </reference>
  <reference>
    <citation>Tan SY, Mei Wong JL, Sim YJ, Wong SS, Mohamed Elhassan SA, Tan SH, Ling Lim GP, Rong Tay NW, Annan NC, Bhattamisra SK, Candasamy M. Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention. Diabetes Metab Syndr. 2019 Jan - Feb;13(1):364-372. doi: 10.1016/j.dsx.2018.10.008. Epub 2018 Oct 10. Review.</citation>
    <PMID>30641727</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>November 20, 2021</last_update_submitted>
  <last_update_submitted_qc>November 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hadeer S. Hassan</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

